Alvotech Hits 52-Week Low as Stock Plummets to $3.31

Alvotech, a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 3.31 on March 23, 2026. This marks a significant decline, with the stock's performance over the past year reflecting a decrease of 76.97%, contrasting sharply with the S&P 500's gain of 16.12% during the same period. The company's market capitalization stands at USD 1,192 million, and it currently has a price-to-earnings (P/E) ratio of 17.00. However, Alvotech's financial metrics indicate challenges, including a negative book value and a return on equity of -39.32%. The company's debt equity ratio is reported at -6.19, suggesting difficulties in managing its debt obligations. Despite a notable annual growth rate in net sales of 256.02% and operating profit growth of 37.21% over the last five years, Alvotech's ability to service its debt remains weak, as evidenced by an average EBIT to interest ratio of -7.56. The stock's performance has consistently underperformed against the S&P 500 over the last three years, highlighting ongoing challenges in its market position.